We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current OPHLY market cap is 5.03B. The company's latest EPS is JPY 85.5416 and P/E is 0.11.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 293.08B | 317.35B | 362.34B | 447.92B | 503.81B |
| Operating Income | 77.35B | 98.34B | 103.25B | 142.06B | 160.39B |
| Net Income | 59.7B | 75.43B | 80.52B | 112.72B | 127.98B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 673.44B | 746.84B | 739.2B | 882.44B | 913.67B |
| Total Liabilities | 105.42B | 105.69B | 77.53B | 134.63B | 115.06B |
| Total Equity | 568.02B | 641.16B | 661.67B | 747.81B | 798.61B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 74.16B | 73.98B | 61.82B | 159.61B | 110.66B |
| Investing | -10.23B | -57.59B | 6.04B | -100.26B | 48.08B |
| Financing | -54.72B | -24.75B | -60.23B | -32.49B | -89.85B |
| Market Cap | 5.03B |
| Price to Earnings Ratio | 0.11 |
| Price to Sales Ratio | 0.03 |
| Price to Cash Ratio | 0.09 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | 2.64% |
| Shares Outstanding | 1.5B |
| Average Volume (1 week) | 1.02M |
| Average Volume (1 Month) | 756.67k |
| 52 Week Change | -42.71% |
| 52 Week High | 6.11 |
| 52 Week Low | 3.27 |
| Spread (Intraday) | 0.17 (4.96%) |
| Company Name | Ono Pharmaceutical Company Ltd (PK) |
| Address |
1-8-2 kyutaromachi chuo, tokyo 541-8564 |
| Website | https://www.ono.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
